Adverse Events With Dabrafenib/Trametinib Combination in Melanoma
Автор: Targeted Oncology
Загружено: 2018-05-29
Просмотров: 447
Описание:
Jeffrey S. Weber, MD, PhD, deputy director of the Perlmutter Cancer Center at NYU Langone Medical Center, discusses the adverse events (AEs) commonly associated with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in the adjuvant setting for patients with BRAF V600E– or V600K–positive stage III melanoma.
According to Weber, the AEs are very similar to those found with the combination in patients with metastatic disease. However, fatigue and fevers are the most difficult to deal with after receiving this combination. Weber says these 2 particular AEs have led to a number of discontinuations of the treatment as it can be debilitating to the patient.
Other AEs that have been seen before with this treatment include uveitis, hepatitis, nausea, vomiting, and diarrhea. Weber notes that fever and fatigue are common with many BRAF/MEK drugs.
For more resources and information regarding anticancer targeted therapies in melanoma: http://www.targetedonc.com/resource-c...
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
